Oligo/amenorrhoeic
|
RCT (level 1b) | Grinspoon et al91 | 45 women with hypothalamic amenorrhoea (ages 18–40) | OC group (35 μg EE+0.18 mg norgestimate, days 1–7; 35 μg EE+0.215 mg norgestimate, days 8–14; 35 μg EE+0.25 mg norgestimate, days 15–21) (n = 25) v placebo (n = 20) for 3 months | NTx, D-PYR | Decrease in NTx and D-PYR in OC treated group (therefore decreased resorption) |
Healthy premenopausal
|
RCT (level 1b) | Pinter et al93 | 41 women (ages 20–27) | 30 μg EE+150 μg levonorgestrel (n = 21) v control (n = 20) for 3 months | Serum BSAP and osteocalcin, urinary D-PYR | OC treated: BB genotype, decrease in osteocalcin; in Bb genotype, decrease in BSAP and osteocalcin; bb genotype, no change. Control: no changes in any genotype |
Cohort (level 2b) | Paoletti et al94 | 30 women (ages 22–30) | 20 μg EE+75 μg gestodene (n = 10) v 30 μg EE+75 μg gestodene (n = 10) v control (n = 10) for 12 months | Urinary PYR, D-PYR | Decrease in PYR, D-PYR in OC-treated groups (suggesting decreased resorption) |
Kitai et al95 | 30 women (mean age 23.7 years) | OC users v non-users | Urinary Ca2+/Cr ratio | Decrease in Ca2+/Cr with OC use (suggesting decreased resorption); effect more pronounced in non-smokers |